

RAKOCZY  
MOLINO  
MAZZOCHI  
SIWIK LLP



08 - 16 - 7

AF IFW

6 WEST HUBBARD STREET  
SUITE 500  
CHICAGO, IL 60610  
www.rmmslegal.com

312-527-2157 main phone  
312-527-4205 main fax

August 15, 2007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22314-1450

**Mail Stop: AF**  
**Art Unit 1625**

Re: U.S. Utility Patent Application  
Application No. 10/761,940; Filing Date: January 21, 2004  
For: **Piperidine Derivatives as NMDA Receptor Antagonists**  
Inventors: Domány *et al.*  
Our Ref: 1000546-0003

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply Under 37 C.F.R. §1.116; and
2. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to us. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents

August 15, 2007

Page 2

It is believed that no fees are due in association with this filing. However, in the event that any fees are necessary, the U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 503626.

Respectfully submitted,

RAKOCZY MOLINO MAZZOCHI SIWIK LLP



Dawn Gardner Krosnick


Attorney for Applicants


Registration No. 44,118

#### CERTIFICATE OF TRANSMISSION/MAILING

I, Patricia A. Richards, hereby certify that this correspondence is being transmitted to the U.S. Patent & Trademark Office via Express Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: August 15, 2007

  
Patricia A. Richards



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: <b>Domány et al.</b>	Confirmation No.: 4047
Application No.: 10/761,940	Art Unit: 1625
Filed: January 21, 2004	Examiner: Chang, Celia C.
For: <b>Piperidine Derivatives as NMDA Receptor Antagonists</b>	Atty. Docket: 1000546-0003

**Amendment and Reply Under 37 C.F.R. § 1.116**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Mail Stop: AF**  
**Art Unit 1625**

Sir:

In reply to the Office Action dated June 7, 2007, Applicants submit the following Reply. This Reply is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims;
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or other fees are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore are hereby authorized to be charged to our Deposit Account No. 50-3626.